Prader-Willi Syndrome (PWS) - Pipeline Review, H1 2018

  • ID: 4461748
  • Drug Pipelines
  • 82 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Insys Therapeutics Inc
  • LG Chem Ltd
  • Millendo Therapeutics Inc
  • OptiNose US Inc
  • Saniona AB
  • Soleno Therapeutics Inc
  • MORE
Prader-Willi Syndrome (PWS) - Pipeline Review, H1 2018

Summary:

The latest pharmaceutical and Healthcarel and Healthcare disease pipeline guide Prader-Willi Syndrome (PWS) - Pipeline Review, H1 2018, provides an overview of the Prader-Willi Syndrome (PWS) (Genetic Disorders) pipeline landscape.

Prader-Willi Syndrome (PWS) is a rare genetic disorder present at birth that results in a number of physical, mental and behavioral problems. Symptoms include poor muscle tone, low levels of sex hormones and a constant feeling of hunger.

Report Highlights:

The latest pharmaceutical and Healthcare latest pipeline guide Prader-Willi Syndrome (PWS) - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Prader-Willi Syndrome (PWS) (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Prader-Willi Syndrome (PWS) (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Prader-Willi Syndrome (PWS) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 5, 2, 5, 1 and 1 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 1 molecules, respectively.

Prader-Willi Syndrome (PWS) (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Report Coverageproprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Prader-Willi Syndrome (PWS) (Genetic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Prader-Willi Syndrome (PWS) (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Prader-Willi Syndrome (PWS) (Genetic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Prader-Willi Syndrome (PWS) (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Prader-Willi Syndrome (PWS) (Genetic Disorders)
Reasons to Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Prader-Willi Syndrome (PWS) (Genetic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Prader-Willi Syndrome (PWS) (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Insys Therapeutics Inc
  • LG Chem Ltd
  • Millendo Therapeutics Inc
  • OptiNose US Inc
  • Saniona AB
  • Soleno Therapeutics Inc
  • MORE
Introduction

Report Coverage

Prader-Willi Syndrome (PWS) - Overview

Prader-Willi Syndrome (PWS) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Prader-Willi Syndrome (PWS) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Prader-Willi Syndrome (PWS) - Companies Involved in Therapeutics Development

Chong Kun Dang Pharmaceutical Corp

Ferring International Center SA

Insys Therapeutics Inc

LG Chem Ltd

Millendo Therapeutics Inc

OptiNose US Inc

Saniona AB

Soleno Therapeutics Inc

Zafgen Inc

Prader-Willi Syndrome (PWS) - Drug Profiles

(metoprolol + tesofensine) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AZP-531 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

beloranib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cannabidiol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

carbetocin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

D-Tagatose - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

diazoxide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

diazoxide choline CR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GLWL-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HM-04 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KAL-671 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

oxytocin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

oxytocin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

setmelanotide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Activate snRNP-N for Prader-Willi Syndrome - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Glycogen Synthase for Prader Willi Syndrome and Glycogen Storage Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

somatropin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ZGN-1258 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Prader-Willi Syndrome (PWS) - Dormant Projects

Prader-Willi Syndrome (PWS) - Discontinued Products

Prader-Willi Syndrome (PWS) - Product Development Milestones

Featured News & Press Releases

Jan 16, 2018: Saniona initiates Phase I study with new Tesomet tablet

Jan 08, 2018: Saniona reports top line results from the Tesomet Phase 2a interim study in Prader-Willi syndrome

Dec 26, 2017: FDA Grants INSYS Therapeutics ‘Fast Track’ Designation for Cannabidiol (CBD) Oral Solution as Investigational Treatment for Prader-Willi Syndrome

Oct 26, 2017: Saniona AB: Saniona decides to perform interim analysis of Tesomet study in patients with Prader-Willi syndrome

Oct 12, 2017: Soleno Therapeutics Receives Positive Opinion from European Orphan Committee for DCCR in Prader-Willi Syndrome

Oct 11, 2017: Soleno Therapeutics Announces Issuance of New U.S. Patent for DCCR Covering Treatment of Hyperphagia in Prader-Willi Syndrome

Sep 25, 2017: Soleno Therapeutics Announces Receipt of Scientific Advice from the European Medicines Agency for DCCR in Prader-Willi Syndrome

Sep 15, 2017: Soleno Therapeutics Presents Updated Safety and Efficacy Data from Clinical Trial of DCCR for Treatment of Prader-Willi Syndrome

Sep 13, 2017: Soleno Therapeutics Announces Issuance of New U.S. Patent for DCCR in Treatment of Prader-Willi Syndrome

Jul 05, 2017: Soleno Therapeutics Announces Successful Completion of FDA Meeting for DCCR in Prader-Willi Syndrome

Apr 03, 2017: Saniona initiates Phase 2a study for Tesomet in Prader-Willi syndrome

Mar 20, 2017: Saniona expects to initiate the planed Phase 2a study for Tesomet in Prader-Willi syndrome in Q2 2017

Nov 07, 2016: Saniona Plans To Initiate Phase 2A Study In Prader-Willi In 2017

Jul 20, 2016: Kalytera Therapeutics Presents New Data Demonstrating KAL671 Ability to Prevent Bone Loss in a Prader-Willi Syndrome Animal Model

Jul 18, 2016: Alize Pharma to present results from AZP-531 Phase II trial in Prader-Willi syndrome at two upcoming scientific conferences

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development for Prader-Willi Syndrome (PWS), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Prader-Willi Syndrome (PWS) - Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2018

Prader-Willi Syndrome (PWS) - Pipeline by Ferring International Center SA, H1 2018

Prader-Willi Syndrome (PWS) - Pipeline by Insys Therapeutics Inc, H1 2018

Prader-Willi Syndrome (PWS) - Pipeline by LG Chem Ltd, H1 2018

Prader-Willi Syndrome (PWS) - Pipeline by Millendo Therapeutics Inc, H1 2018

Prader-Willi Syndrome (PWS) - Pipeline by OptiNose US Inc, H1 2018

Prader-Willi Syndrome (PWS) - Pipeline by Saniona AB, H1 2018

Prader-Willi Syndrome (PWS) - Pipeline by Soleno Therapeutics Inc, H1 2018

Prader-Willi Syndrome (PWS) - Pipeline by Zafgen Inc, H1 2018

Prader-Willi Syndrome (PWS) - Dormant Projects, H1 2018

Prader-Willi Syndrome (PWS) - Discontinued Products, H1 2018

List of Figures:

Number of Products under Development for Prader-Willi Syndrome (PWS), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Chong Kun Dang Pharmaceutical Corp
  • Ferring International Center SA
  • Insys Therapeutics Inc
  • LG Chem Ltd
  • Millendo Therapeutics Inc
  • OptiNose US Inc
  • Saniona AB
  • Soleno Therapeutics Inc
  • Zafgen Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll